pyrazines has been researched along with bms345541 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H | 1 |
| Alsina, M; Beg, AA; Boulware, D; Chen, DT; Dalton, WS; Hazlehurst, LA; Mathews, L; Oliveira, V; Shain, KH; Villagra, A; Wang, X; Yarde, DN | 1 |
| Bruserud, Ø; Ersvaer, E; Hatfield, KJ; Kittang, AO; Lassalle, P; Reikvam, H | 1 |
| Bosman, MC; Quax, WJ; Schuringa, JJ; Vellenga, E | 1 |
| Anderson, KC; Hide, M; Hideshima, H; Hideshima, T; Ikeda, H; Iwasaki, A; Yoshida, Y | 1 |
5 other study(ies) available for pyrazines and bms345541
| Article | Year |
|---|---|
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2010 |
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Gene Expression; Humans; Imidazoles; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Quinoxalines; Transcription Factor RelB | 2009 |
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antibodies; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Female; Fibroblasts; Hepatocyte Growth Factor; Humans; Imidazoles; Interleukin-8; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Osteoblasts; Proteoglycans; Pyrazines; Quinoxalines; Receptor Cross-Talk; Receptor, TIE-2; Signal Transduction | 2010 |
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Coculture Techniques; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; I-kappa B Kinase; Imidazoles; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Primary Cell Culture; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinoxalines; Recombinant Proteins; RNA, Small Interfering; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2013 |
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Kinase; I-kappa B Proteins; Imidazoles; MCF-7 Cells; NF-KappaB Inhibitor alpha; Phosphorylation; Pyrazines; Quinoxalines; Transcription Factor RelA | 2014 |